With Manipal Hospital Enterprise getting the go-ahead from Fortis Healthcare’s Board to take over the latter’s hospitals, here’s a list of major mergers and acquisitions in the pharmaceuticals sector.
As Fortis Healthcare’s Board has approved the de-merger of its hospitals business to Manipal Hospital Enterprises, Dr Ranjan Pai and TPG are expected to invest a whopping Rs 3,900 crore in Manipal Hospitals.
Here’s a list of major mergers and acquisitions (M&As) in the pharmaceuticals sector:
Sun Pharma-Ranbaxy merger: In a USD 4 billion deal, Sun Pharma is on track to unlock synergies of USD 300 million by merging Ranbaxy by end-FY18.
Sun Pharma-Taro acquisition: In September 2010, the Mumbai-headquartered company acquired the US-based pharma firm in a USD 273 million deal. Taro has been one of Sun’s most lucrative acquisitions, with payback within 3 years and return-of-capital of 641 percent according to moneycontrol.com.
Torrent Pharma-Elder portfolio acquisition: In a USD 323 million deal, Torrent sought to expand its India portfolio and scale up sub-optimal products. The deal was a hit for Torrent with 23 percent CAGR of Elder’s brands over FY14-17.
Jubilant-Draxis acquisition: In April 2008, Jubilant acquired Draxis in a USD 255 million deal. The acquisition was turned profitable from the second year. However, the US launch of Ruby-Fill, expected in 2010 at the time of acquisition, was delayed and the product was eventually launched in 2017.
Aurobindo Pharma-Natrol acquisition: To foray into nutraceuticals in the US, the Hyderabad-headquartered firm acquired Natrol in a USD 132.5 million deal.
Aurobindo Pharma – Actavis Western Europe biz acquisition: In 2014, Aurobindo took over Actavis in a EUR 30 million deal to expand its presence and portfolio in Europe.
Abbott-Piramal acquisition: Deal size – USD 3.7 billion.
Lupin-Gavis acquisition: Deal size – USD 880 million.
Cipla-InvaGen/Exelan acquisition: Deal size – USD 550 million.
Here are some M&As that are in progress:
Dr Reddy’s-Teva (8 ANDAs/generic filings): Deal size – USD 350 million.
Strides Arcolab-Shasun merger: Deal size – USD 323 million.
Piramal-Mallinckrodt: Deal size – USD 273 million
Dr Reddy’s – Betapharm acquisition: Deal size – USD 571 million.
